Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared wit
Go back to Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared wit| (NASDAQ: ELDN) | Delayed: 3.74 +0.02 (0.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.72 | 52 Week High | $ | |||
| Open | $3.84 | 52 Week Low | $ | |||
| Day High | $3.84 | P/E | N/A | |||
| Day Low | $3.62 | EPS | $ | |||
| Volume | 614,383 | |||||
